



## **Collaborative Innovation for the Future of Health**

### **Curriculum Vitae of the Main Speakers**

#### **HITOSHI KUBONIWA PhD**

Hitoshi works for Chugai Pharmaceutical Co., Ltd. as corporate advisor and serve for Japan Bioindustry Association as chairman of the steering committee. Prior to current position, He has been general manager of Pharmaceutical Technology Division for process development and commercial manufacturing in both biologics and small molecules field at Chugai. He has 37 year's experiences in pharmaceutical industry, most of it with Chugai in discovery research, business development and senior management role of pharmaceutical technology. He obtained a Ph.D. from Tokyo Institute of Technology in polymer chemistry.

#### **LODE LAUWERS PhD**

Lode Lauwers is Senior Vice President Business Development and Strategy in IMEC, the nanoelectronics R&D Center in Leuven, Belgium.

He oversees Corporate Business Development of IMEC's Semiconductor Technology Business Lines, being responsible for imec's R&D collaboration revenue in semiconductor technology and giving guidance to a worldwide Business and Partnership Development team. In the area of CMOS technology, he is responsible for IMEC business offerings and strategy, covering worldwide collaborations in the eco-system of leading IC manufacturers, foundries, equipment and material suppliers and design and system houses.

Since he joined IMEC in 2005, he had various roles in IMEC's technology business and sales and partner relation management.

Earlier, he has been general manager of an ASIC design house, part of a US-based ASSP provider for the telecom industry, and scientific advisor for government funding in local and European cooperative networks in micro-electronics and telecommunications.

He has a PhD in Electrical Engineering from KU Leuven.

#### **PIERRE MEULIEN, PhD**

Dr Pierre Meulien is Executive Director of the Innovative Health Initiative (IHI), a partnership between the European Union and Europe's health-related industries.

Dr Meulien has decades of experience in the life science sector, having worked in both the public and private sectors and on both sides of the Atlantic.

Having acquired a PhD in molecular biology from the University of Edinburgh, Scotland, he carried out a post-doctoral fellowship at the Institut Pasteur in Paris, France. He then moved to the private sector, working with the French biotechnology company Transgene, and Aventis Pasteur (now Sanofi Pasteur).

From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked medical schools and teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research.



From 2007 to 2010, he was Chief Scientific Officer at Genome British Columbia. In 2010 he became President and CEO of Genome Canada, where he raised significant funds for the organisation and oversaw the launch of novel projects and networks in the field of genomics-based technologies.

He returned to Europe in 2015 to take up the post of Executive Director of the Innovative Medicines Initiative (IMI), the fore runner of IHI. In that role, he brought new partners into the organisation, including philanthropic organisations and companies. He also oversaw the launch of wide-ranging programmes on big data, neurological conditions, and antimicrobial resistance, as well as a rapidly-launched portfolio of projects on COVID diagnostics and treatments, all of which have had global reach.

More recently, he led the organisation throughout the transition from IMI to IHI.

Dr Meulien has Irish nationality.

<https://www.linkedin.com/in/pierre-meulien-a762a15/>

[www.linkedin.com/company/innovative-health-initiative/](https://www.linkedin.com/company/innovative-health-initiative/)

### **SOFIE PATTIJN PhD**

Sofie Pattijn (CTO and Founder, ImmunXperts) has over 25 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immune oncology and Cell and Gene Therapy products. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

### **GEOFFREY POT**

Geoffrey Pot, Vice President and Site Head of Takeda's Global Manufacturing Site in Lessines, Belgium

Geoffrey Pot holds a Master's degree in Pharmacy/Industrial Pharmacy and a certification in International Management. He has over 15 years of experience in the biotechnology industry. Geoffrey started his career in the Quality department at Baxter, where he held positions of increasing responsibility. He then had the opportunity to continue his development within the Manufacturing department and led several international teams at Baxter, Shire and Takeda.

Passionate about digitalization and innovation, has led several initiatives globally to ensure innovation and strategy deployment across manufacturing plants.

The Global Manufacturing Site of Takeda in Lessines with its 1,200 employees has the mission to serve patients with rare diseases and other specialised conditions. It is a Centre of Excellence for immunoglobulin purification, with filling and packaging capacity for plasma-derived therapies and packaging capacity for haematology products reaching patients in over 80 countries.

In September 2019, Mr. Pot was elected President of bio.be, the industry association of the biotechnology sector in Belgium.